Devices
Singlera ‘Breakthrough’ on Pancreatic Cancer Assay
FDA has granted Singlera Genomics a breakthrough device designation for its PDACatch assay, a DNA methylation-based liquid biopsy assay for detecting pancreatic adenocarcinoma in individuals at high risk for the disease. The device is based on Singlera's MethylTitan platform, which “utilizes a proprietary library construction approach and